Ritedose Secures FDA Approval for Generic Tobramycin Inhalation Solution, Expanding Cystic Fibrosis Treatment Access
核心洞察
The FDA approved Ritedose Corporation (搜索)'s manufacturing and distribution of generic Tobramycin Inhalation Solution for treating Pseudomonas aeruginosa infections in cystic fibrosis patients aged six years and older.
This marks Ritedose's first cystic fibrosis product and establishes the company as having the largest nebulized drug portfolio in the United States.
The preservative-free formulation is packaged as 300 mg doses in 5 ml ampules and is now available for purchase, expanding affordable access to this critical antibiotic therapy.
The Ritedose Corporation (搜索) announced that the U.S. Food and Drug Administration has approved its manufacturing and distribution of generic Tobramycin Inhalation Solution, marking a significant expansion into cystic fibrosis therapeutics. The approval enables treatment of patients six years and older with Pseudomonas aeruginosa infections, a common and serious bacterial complication in cystic fibrosis patients.
Strategic Portfolio Expansion
The addition of Tobramycin represents Ritedose's first entry into the cystic fibrosis treatment market and positions the company as offering the largest nebulized drug portfolio in the United States. "With the addition of Tobramycin, Ritedose now provides the largest nebulized drug portfolio in the country," said CEO Jody Chastain. "Our recent investments in expanded facilities, cold chain processes and an additional packaging line have given us unparalleled capabilities in sterile manufacturing."
Ritedose Pharmaceuticals, the generics division of Ritedose, will market the medication after licensing the drug's Abbreviated New Drug Application (ANDA) from Hikma Pharmaceuticals. The parent company operates as the largest sterile contract development manufacturing organization (CDMO) in the U.S., specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology.
Product Specifications and Availability
The approved Tobramycin formulation is an aminoglycoside antibiotic indicated for treating serious bacterial infections, including Pseudomonas aeruginosa, in adults and pediatric patients six years of age and older. The Ritedose version is preservative-free and packaged as 300 mg doses in 5 ml ampules, designed for administration through nebulizer devices. The medication is now available for purchase.
"Now with Tobramycin in our portfolio, we can provide affordable, safe and reliable medications to patients with serious bacterial infections, expanding access to this critical therapy," Chastain continued. "We're also proud to strengthen supply chain resilience with the addition of a broad-spectrum antibiotic that is produced here in the United States."
Continued Generic Drug Pipeline Success
This approval represents the third generic drug announcement from Ritedose in 2025, demonstrating sustained momentum in the company's expansion strategy. In April, Ritedose Pharmaceuticals received approval to manufacture generic Formoterol Fumarate Inhalation Solution for maintenance treatment of chronic obstructive pulmonary disease (COPD).
In March, the company secured approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL), for patients over 12 years of age experiencing acute bronchospasm attacks or reversible obstructive airway disease. This addition completed Ritedose's comprehensive albuterol treatment portfolio and addressed a nationwide shortage of the essential medication.
Manufacturing Capabilities
Ritedose's specialized Blow Fill Seal technology ensures sterile, consistent, and safe unit dose delivery across its product portfolio. The company's manufacturing process supports molecule development from clinical trials through commercialization of both branded and generic inhalation and ophthalmic medications, partnering with leading pharmaceutical companies to deliver medications aimed at improving patient outcomes.